Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA
Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.
How this was made

The 30-second read
Why it matters
The earnings call provides fresh guidance on membership trends, Medicaid headwinds, and premium exposure, which are key inputs for valuation models.
Market read
The disclosed guidance and operational updates are likely to influence Astrana Health's stock price in the near term, with mixed signals from Medicaid pressure and growth opportunities.
What to watch
The $4.45 B premiums‑at‑risk metric may signal future revenue visibility improvements if ACO contracts perform as expected.
Background
Astrana Health is a U.S. health‑technology company providing value‑based care solutions, with revenue driven by Medicaid, Medicare Advantage, and care‑enablement contracts.
Ticker impact
Astrana Health disclosed a mid‑single‑digit EBITDA headwind from Medicaid and $4.45 B premiums at risk for 2026, plus new client wins and membership growth guidance during its Q3 2026 earnings call.
potential modest downside as market prices in Medicaid headwinds, offset by upside from care enablement growth and premium‑at‑risk disclosure.
The new guidance numbers are material for valuation, but the net effect is ambiguous, leading to limited directional pressure.
Market effects
Highlights ongoing challenges in Medicaid for health‑tech firms while underscoring growth potential in Medicare Advantage and care‑enablement services.
California and Connecticut market developments may influence regional health‑care providers and insurers.
Limited to U.S. health‑care sector; no broader macro impact.
Counterpoint
Investors could view the Medicaid attrition as temporary and focus on the strong Medicare Advantage margins and care enablement revenue, positioning for upside.
Key entities
- ExecutiveBrandon Sim
President and CEO of Astrana Health, provided guidance and commentary.
- ExecutiveChan Bhasho
Chief Operating and Financial Officer, discussed Medicare Advantage risk‑adjustment sweeps.



